Equity Overview
Price & Market Data
Price: $1.36
Daily Change: -$0.04 / 2.94%
Daily Range: $1.28 - $1.41
Market Cap: $162,876,672
Daily Volume: 92,511
Performance Metrics
1 Week: -3.76%
1 Month: -25.15%
3 Months: -27.68%
6 Months: -29.28%
1 Year: 42.22%
YTD: -14.09%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.